Service of Stomatology, University General Hospital of Valencia, Spain.
Curr Pharm Des. 2012;18(34):5470-80. doi: 10.2174/138161212803307617.
Oral Lichen Planus (OLP) is a chronic inflammatory condition implicating T cell-mediated cytotoxicity, and involving oral mucosal surfaces. Several therapeutic regimens have been evaluated to treat OLP and pain related, but often without high level of evidence. Topical formulations are the favourite for the majority of cases; bioadhesive formulations have been considered very useful and practical for local drug delivery in oral mucosa, due to the increased residence time on the oral mucosa of the dosage forms and better therapeutic efficacy. In this narrative review, authors try to illustrate the current topical managements for OLP from the accessible literature on this topic. Steroids are very helpful in discomfort and making better quality of life: they are considered the first-line treatment even if they could cause secondary candidosis, and sometimes bad taste, nausea, dry mouth, sore throat or swollen mouth. Other substances or devices by topical administration are adopted especially when the first line approach is refractory. This is the case when retinol with its synthetic and natural analogues (retinoids), hyaluronic acid, or Aloe Vera are chosen. Recent topical applications for OLP therapy include phototherapy and low/high energy pulsing light; the treatment with extracorporeal photochemotherapy is also reasonable and promising. Finally, calcineurin inhibitors (i.e. cyclosporine, tacrolimus and pimecrolimus), antioxidant and biologics (i.e alefacept, efalizumab, basiliximab, TNF-α inhibitors - infliximab, rituximab) may be alternative approaches when OLP does not respond to the standard protocols. In this scenario, there are several studies on molecules different from glucocorticosteroids, but not sufficient or statistically adequate to justify their evidence-based use in OLP; large randomized placebo controlled trials are required to evaluate the safety and effectiveness of these non conventional therapies. In conclusion, since OLP is a chronic disease and requires long-term management, the dental/medical practitioner, who treats OLP patients, needs to know the natural history of OLP, how to monitor, and how to treat, taking in account all of the available modalities conventional and not, with pros and cons.
口腔扁平苔藓(OLP)是一种慢性炎症性疾病,涉及 T 细胞介导的细胞毒性,涉及口腔黏膜表面。已经评估了几种治疗方案来治疗 OLP 和相关疼痛,但通常没有高水平的证据。局部制剂是大多数病例的首选;由于剂型在口腔黏膜上的停留时间增加和更好的治疗效果,生物粘附制剂已被认为对于口腔黏膜的局部药物递送非常有用和实用。在这篇叙述性综述中,作者试图从关于该主题的可访问文献中说明 OLP 的当前局部治疗方法。类固醇在不适和提高生活质量方面非常有帮助:它们被认为是一线治疗方法,即使它们可能导致继发性念珠菌病,有时还会引起不良口味、恶心、口干、喉咙痛或口腔肿胀。当一线方法无效时,会采用其他物质或设备进行局部给药。当选择视黄醇及其合成和天然类似物(类视黄醇)、透明质酸或芦荟时就是这种情况。OLP 治疗的最近局部应用包括光疗和低/高能脉冲光;体外光化学疗法的治疗也是合理且有前途的。最后,钙调神经磷酸酶抑制剂(即环孢素、他克莫司和吡美莫司)、抗氧化剂和生物制剂(即阿昔单抗、依氟鸟氨酸、巴利昔单抗、TNF-α 抑制剂 - 英夫利昔单抗、利妥昔单抗)在 OLP 对标准方案无反应时可能是替代方法。在这种情况下,有许多关于糖皮质激素以外的分子的研究,但还不足以或在统计学上不足以证明它们在 OLP 中的基于证据的使用;需要进行大型随机安慰剂对照试验来评估这些非传统疗法的安全性和有效性。总之,由于 OLP 是一种慢性疾病,需要长期管理,因此治疗 OLP 患者的牙科/医疗从业者需要了解 OLP 的自然病史,如何进行监测以及如何治疗,同时考虑到所有现有的常规和非常规治疗方式,权衡利弊。